TP53 and cancer: Inhibition of kinases involved in the G2 checkpoint, including aurora kinase A (AURKA) (; ref. 15), aurora kinase B (AURKB) (; ref. 16), and checkpoint kinase 1 (Chk1; ref. 17), induces cell death in TP53-mutated cancer cells, and Chk1 inhibition has induced synthetic lethality when combined with cisplatin (18) or inhibition of the aurora kinases (19) in cancers characterized by frequent TP53 mutations.